

REMARKS

The present invention provides 1-aryl- or 1-alkylsulfonylheterocyclylbenzazole compounds of formula I, and the therapeutic use thereof for the treatment of CNS disorders related to or affected by the 5-hydroxytryptamine-6 receptor.

Claims 1, 3-7, 9, 10, 12 and 14-23 are pending in this application. Claims 7, 19 and 22 have been amended. Claims 2, 8-11 and 13 have been cancelled.


Claims 7 and 10 have been rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention. Claim 10 has been rejected under 35 U.S.C. § 112, first paragraph and second paragraph, as both containing subject matter which was not described in the specification in sufficient manner for the enablement of one skilled in the art and for being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner contends that the method of claim 7 drawn to CNS disorders related to or affected by the 5-HT6 receptor is unduly broad and lacks sufficient enablement in the specification for one of ordinary skill in the art and in particular wherein said disorder is a cognitive disorder. Further, the Examiner states that the method of claim 10, in particular the method of treating Parkinson's disease, is not enabled nor sufficiently described..

Applicants respectfully traverse the rejections. Claim 7 has been amended to embrace the limitations of claim 9, i.e. claim 7 is now directed specifically to a method for the treatment of schizophrenia and depression. Claim 10 has been cancelled.

In conclusion, Applicants believe that the Examiner's rejections under 35 U.S.C. § 112, first paragraph and second paragraph have been overcome in view of the amendments to the claims, as shown hereinabove. Applicants respectfully request the Examiner to enter the above amendments, consider the above remarks, withdraw the rejections and allow the application.

Favorable treatment of the application is earnestly solicited.

Respectfully submitted,



Barbara L. Lences  
Agent for Applicants  
Reg. No. 41,148

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (732) 274-4678